Thursday, March 24, 2016
With Andrew Witty's Departure, Will GlaxoSmithKline Say Goodbye to Fraud?
Glaxo has made headlines during CEO Andrew Witty’s tenure, but for all the wrong reasons. The company reportedly is considering external as well as internal candidates to replace Witty, but it should scratch internal prospects off the list.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment